Share this video  

WCM/EADO 2021 | Sentinel node tumor burden for prognostication in melanoma

Alexander van Akkooi, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, summarizes his presentation at WCM/EADO 2021 on the use of sentinel node characteristics as prognostic factors in melanoma. Dr van Akkooi outlines use of the Rotterdam criteria and highlights it’s use in trials and in clinical practice. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.


Alexander van Akkooi, MD, PhD, discloses links to Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Sirius Medical and 4SC.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter